English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Haemagglutinating inhibiting antibody (HAI) responses were determined and clinical reactions recorded in 162 adult volunteers who received either 1 or 2 intranasal doses of 10(7-0) EID50 WRL 105 strain live influenza vaccine or placebo. After administration of a single dose of vaccine significant antibody responses were obtained in 69 (70%) of 98 volunteers with initial antibody titres of less than or equal to 1/20. Of the 70 volunteers who received a second dose of vaccine, 62 provided a further post-vaccination sample of serum, and only 3 (4-8%), who had not responded to the first dose of vaccine, produced a significant antibody response. Local, upper respiratory and constitutional symptoms were recorded more frequently after the administration of a first dose of vaccine than after placebo or a second dose of vaccine. The symptoms were of a minor nature except in one volunteer who, after the first dose of vaccine, developed influenzal symptoms followed by bronchitis.

WRL 105 strain live attenuated influenza vaccine; comparison of one and two dose schedules